EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2026)
Events

EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2026)

The EFMC is the main organization for the European Medicinal Chemistry and Chemical Biology community, with 31 member societies and about 9.000 members. Its biennial EFMC Medicinal Chemistry is a key symposium in the field of medicinal chemistry and drug discovery and it traditionally attracts around 1.000 participants both from industry and academia. 

The scientific programme will run over 5 days and will include plenary sessions and cover a wide range of selected topics split into 3 parallel sessions.

Themes

  • Chemical Biology
  • Medicinal Chemistry
  • Enabling Technologies

Lectures Include

Chemical Biology

  • Chemical Proteomics in Translational Drug Discovery
    Chair: Prof. Mario van der Stelt, University of Leiden, NL
  • Next-Gen Conformationally Constrained Peptides
    Chair: Prof. Kristian Stromgaard, University of Copenhagen, DK
  • Small Molecule Regulation of Transcriptional Factors (CPA Session)
    Chair: Prof. Ke Ding, University of Chinese Academy of Sciences, CN
  • Exploiting the Functions of Structures of DNA & RNA Binding Proteins
    Chair: Dr Josef Messinger, Orion Pharma, FI
  • Drugging the Undruggable with Covalent Ligands (ACS MEDI Session I)
    Chair: Prof. Daniel Harki, University of Minnesota, US
  • Smart Reactivity: Chemical Triggers for Next-Gen Probes and Prodrugs (ICBS Session)
    Chair: Dr Boris Vauzeilles, Institut de Chimie des Substances Naturelles, FR
  • Underexploited Targets: Glycan-Binding Receptors and Glycosyltransferases
    Chair: Prof. Marko Anderluh, University of Ljubljana, SI
Medicinal Chemistry

  • Anti-Infectives – Novel Targets, New Modalities
    Chair: Prof. Stefan Laufer, University of Tübingen, DE
  • Innate Immune Sensing and Inflammasome Pathways
    Chair: Dr Daniel Oehlrich, Johnson & Johnson, BE
  • New Approaches to Tackling CNS Disorders
    Chair: Dr Chiara Borsari, University of Milan, IT
  • Exploiting Metabolic Vulnerabilities in Cancer
    Chair: Dr Marina Virgili, AtG Therapeutics, ES
  • Recent Progress in the Development of Radiopharmaceuticals
    Chair: Dr Anna Junker, European Institute of Molecular Imaging, DE
  • It Takes Two: Targeting Synthetic Lethalities in Cancer with DNA Damage Response Inhibitors (ACS MEDI Session II)
    Chair: Prof. Thomas Martínez, UC Irvine, US
  • Approaches to Safe and Sustainable Pharmaceuticals
    Chair: Dr Fides Benfatti, Syngenta, CH
Enabling Technologies

  • Antibody-Drug Conjugates: Advances in Targeted Therapies
    Chair: Dr Sophie Bertrand, GSK, UK
  • Next Generation Structure-Based Drug Design
    Chair: Dr Andrew Woodhead, Astex Pharmaceuticals, UK
  • Exploring New Areas of Chemical Space for Drug Discovery
    Chair: Dr Stefan Schiesser, AstraZeneca, SE
  • New Approaches to Allosteric Modulators
    Chair: Dr Adrian Hall, UCB BioPharma, BE
  • Direct-to-Biology Approaches for Drug Discovery
    Chair: Dr Julien Lefranc, Merck Healthcare KGaA, DE
  • Automated Chemical Synthesis: Advancing Sustainable Industrials Practices Through Precision and Efficiency (AFMC Session)
    Chair: Prof. Kyungsoo Oh, Chung-Ang University, KR
  • EFMC² Session: Augmented or Artificial Molecular Design?
    Chair: Dr Hayley Binch, F. Hoffmann-La Roche, CH

 

 

Event Details

Related Content